First Header Logo Second Header Logo

Elizabeth Alli PhD

TitleAssistant Professor
InstitutionWake Forest School of Medicine
DepartmentCancer Biology
Address
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Stanford University School of Medicine, Stanford, CAPostdoc2011Medicine-Oncology
    Rutgers University-Biomedical and Health Sciences, New Brunswick, NJPh.D.2006Molecular and Cellular Pharmacology
    Rutgers University-Biomedical and Health Sciences, New Brunswick, NJM.S.2001Molecular and Cellular Pharmacology
    University of Southern California, Los Angeles, CAB.S.1995Exercise Science (major); Chemistry (minor)
    Collapse awards and honors
    2015 - 2019K22 Transition Career Development Award, NIH/NCI
    2017 - 2018Daryl and Marguerite Errett Discovery Award, Errett Fisher Foundation
    2017 - 2017Concept Award, Wake Forest School of Medicine
    2015 - 2016Spark Scholar Award, Stanford University School of Medicine
    2014 - 2014Susan G. Komen Scholar-in-Training Award, American Association for Cancer Research
    2008 - 2011Postdoctoral Fellowship Award , Susan G. Komen Foundation
    2010 - 2010Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine
    2009 - 2009Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine
    2008 - 2008Bristol-Myers Squibb Oncology Scholar-in-Training Award, American Association for Cancer Research
    2007 - 2007Dean’s Postdoctoral Fellowship, Stanford University School of Medicine
    2007 - 2007Helena Anna Henzl Gabor Young Women in Science Travel Award, Stanford University School of Medicine
    2005 - 2005Merck Scholar-in-Training Award, American Association for Cancer Research
    2002 - 2002Award for Scientific Excellence, State of New Jersey
    2001 - 2001Gallo Award for Cancer Research, State of New Jersey
    2000 - 2000Young Investigator’s Award, UMDNJ-Department of Pharmacology

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    K22CA181550     (ALLI, ELIZABETH)Sep 15, 2015 - Aug 31, 2019
    NIH
    Targeting defective DNA repair for the prevention of BRCA1-associated cancers
    Role: Principal Investigator
    R01CA227261     (KELLY, DEBORAH F)Mar 1, 2018 - Feb 28, 2023
    NIH
    Hot Spot Analysis of the Breast Cancer Susceptibility Protein
    Role: Co-Investigator
    R01CA219700     (KELLY, DEBORAH F)Jun 1, 2018 - May 31, 2023
    NIH
    Multi-scale imaging of breast cancer proteins during DNA repair
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Swanner J, Fahrenholtz CD, Tenvooren I, Bernish BW, Sears JJ, Hooker A, Furdui CM, Alli E, Li W, Donati GL, Cook KL, Vidi PA, Singh R. Silver nanoparticles selectively treat triple-negative breast cancer cells without affecting non-malignant breast epithelial cells in vitro and in vivo. FASEB Bioadv. 2019 Oct; 1(10):639-660. PMID: 32123812.
      Citations:    
    2. Liang Y, Dearnaley WJ, Alden NA, Solares MJ, Gilmore BL, Pridham KJ, Varano AC, Sheng Z, Alli E, Kelly DF. Correcting errors in the BRCA1 warning system. DNA Repair (Amst). 2019 01; 73:120-128. PMID: 30503669.
      Citations:    
    3. Alli E, Ford JM. BRCA1: Beyond double-strand break repair. DNA Repair (Amst). 2015 Aug; 32:165-171. PMID: 25956865.
      Citations:    
    4. Alli E, Ford JM. BRCA1: a movement toward cancer prevention. Mol Cell Oncol. 2015 Jul-Sep; 2(3):e979685. PMID: 27308455.
      Citations:    
    5. Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res. 2014 Nov 01; 74(21):6205-15. PMID: 25217519.
      Citations:    
    6. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013 Nov; 142(2):389-98. PMID: 24166281.
      Citations:    
    7. Alli E, Ford JM. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012 May 01; 11(5):522-4. PMID: 22425348.
      Citations:    
    8. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011 Jul 19; 11:7. PMID: 21771338.
      Citations:    
    9. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15; 70(20):7970-80. PMID: 20798217.
      Citations:    
    10. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009 Apr 15; 69(8):3589-96. PMID: 19351835.
      Citations:    
    11. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007 May; 71(5):1233-40. PMID: 17272681.
      Citations:    
    12. Hait WN, Rubin E, Alli E, Goodin S. Tubulin . Tubulin Targeting Agents. Update on Cancer Therapeutics. 2007; 2(1):1-18. View Publication.
    13. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007 Feb 15; 26(7):1003-12. PMID: 16909102.
      Citations:    
    14. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002 Dec 01; 62(23):6864-9. PMID: 12460900.
      Citations:    
    15. Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002 May; 8(5):1057-64. PMID: 12006519.
      Citations:    
    Alli's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (92)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (47)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _